Tag - United Therapeutics

Markets

Dawson James starts CollPlant Biotechnologies at buy; PT $9

Dawson James Securities initiated coverage of CollPlant Biotechnologies (NASDAQ:CLGN) with a “buy” rating and $9 price target. The stock closed at $4.62 on Nov. 1. CollPlant’s technology platform mass produces...

November 4, 2019

Developments

iBio inks 3D bioprinting agreement with United Therapeutics’ subsidiary, Lung Biotechnology PBC

iBio (NYSE AMERICAN:IBIO) entered into an agreement with Lung Biotechnology, a subsidiary of United Therapeutics (NASDAQ:UTHR), to produce recombinant human collagen (rhCollagen)-based bioink for 3D bioprinted organ...

August 19, 2019

Tag - United Therapeutics

Dawson James starts CollPlant Biotechnologies at buy; PT $9

iBio inks 3D bioprinting agreement with United Therapeutics’ subsidiary, Lung Biotechnology PBC

General

More